Idenix Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Centre National De La Recherche Scientifique

Universitè De Montpellier

Guillaume Brandt

Cyril B Dousson

David Dukhan

Francois-Rene Alexandre

Christophe Parsy

Jean-Laurent Paparin

Gilles J Gosselin

Dominique Surleraux

Claire Pierra

Houcine Rahali

Thierry Convard

Daniel Da Costa

Michel Derock

Adel M Moussa

Stephane L Bogen

Benjamin Alexander Mayes

Alistair James Stewart

Gilles Gosselin

Rachid Rahali

Jean-François Griffon

Alistar James Stewart

François-René Alexandre

Claire Pierra Rouviere

Christophe Claude Parsy

The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R, R, R, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient. 

Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-cyano, azido or amino nucleosides according to Formula 1001 or 2001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form, or polymorphic form thereof, wherein Base, W, Rand Rare as described herein.

Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of HCV

Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3'-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, R, R, R, Rand Z are as defined herein. 

3'-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. 

5,5-fused arylene or heteroarylene hepatitis C virus inhibitors

Growing community of inventors

Montpellier, France

Guillaume Brandt